PLx Pharma, Inc. (PLXP): Price and Financial Metrics


PLx Pharma, Inc. (PLXP): $2.92

0.33 (+12.74%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PLXP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PLXP POWR Grades


  • PLXP scores best on the Value dimension, with a Value rank ahead of 48.47% of US stocks.
  • The strongest trend for PLXP is in Quality, which has been heading down over the past 179 days.
  • PLXP ranks lowest in Momentum; there it ranks in the 4th percentile.

PLXP Stock Summary

  • For PLXP, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
  • With a year-over-year growth in debt of -100%, PLx Pharma Inc's debt growth rate surpasses only 0% of about US stocks.
  • As for revenue growth, note that PLXP's revenue has grown 26,873.38% over the past 12 months; that beats the revenue growth of 99.88% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to PLx Pharma Inc, a group of peers worth examining would be LPCN, PRTA, KROS, MICT, and ZOM.
  • Visit PLXP's SEC page to see the company's official filings. To visit the company's web site, go to plxpharma.com.

PLXP Valuation Summary

  • In comparison to the median Healthcare stock, PLXP's price/sales ratio is NA% NA, now standing at NA.
  • PLXP's price/sales ratio has moved NA NA over the prior 91 months.
  • PLXP's price/sales ratio has moved NA NA over the prior 91 months.

Below are key valuation metrics over time for PLXP.

Stock Date P/S P/B P/E EV/EBIT
PLXP 2021-08-31 NA 11.9 -11.2 -10.1
PLXP 2021-08-30 NA 11.9 -11.2 -10.1
PLXP 2021-08-27 NA 12.0 -11.3 -10.3
PLXP 2021-08-26 NA 11.3 -10.6 -9.6
PLXP 2021-08-25 NA 11.3 -10.7 -9.6
PLXP 2021-08-24 NA 11.6 -10.9 -9.9

PLXP Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at 45.55%.
  • Its 5 year net income to common stockholders growth rate is now at 53.87%.
  • Its 2 year net income to common stockholders growth rate is now at -5.11%.
PLXP's revenue has moved up $6,616,100 over the prior 67 months.

The table below shows PLXP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 6.6161 -21.27666 -60.70349
2021-06-30 0 -15.40224 -42.68728
2021-03-31 0.027907 -12.75076 -29.98653
2020-12-31 0.03043 -12.24359 -16.94795
2020-09-30 0.054323 -13.36 -10.77427
2020-06-30 0.095429 -13.39286 -5.755396

PLXP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PLXP has a Quality Grade of C, ranking ahead of 39.31% of graded US stocks.
  • PLXP's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
  • HSTO, ABBV, and AGTC are the stocks whose asset turnover ratios are most correlated with PLXP.

The table below shows PLXP's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 NA 361.591
2021-03-31 0.001 1 162.554
2020-12-31 0.002 1 82.828
2020-09-30 0.003 1 -48.371
2020-06-30 0.005 1 -6.788
2020-03-31 0.012 1 -5.712

PLXP Price Target

For more insight on analysts targets of PLXP, see our PLXP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $21.50 Average Broker Recommendation 1.5 (Moderate Buy)

PLXP Stock Price Chart Interactive Chart >

Price chart for PLXP

PLXP Price/Volume Stats

Current price $2.92 52-week high $21.50
Prev. close $2.59 52-week low $1.92
Day low $2.46 Volume 180,800
Day high $2.96 Avg. volume 245,989
50-day MA $3.57 Dividend yield N/A
200-day MA $9.80 Market Cap 80.41M

PLx Pharma, Inc. (PLXP) Company Bio


PLx Pharma, Inc. is a late-stage specialty pharmaceutical company developing aspirin products that use its patented drug delivery system, which targets delivery of APIs to various portions of the gastrointestinal tract. This has the potential to improve the absorption of many drugs and to reduce acute GI side effects associated with aspirin and ibuprofen, and potentially other drugs.


PLXP Latest News Stream


Event/Time News Detail
Loading, please wait...

PLXP Latest Social Stream


Loading social stream, please wait...

View Full PLXP Social Stream

Latest PLXP News From Around the Web

Below are the latest news stories about PLx Pharma Inc that investors may wish to consider to help them evaluate PLXP as an investment opportunity.

PLx Pharma Inc. to Discuss 2021 Fourth Quarter Financial Results on March 11, 2022 Conference Call and Provide Business Update

SPARTA, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (ref

Yahoo | February 22, 2022

Is PLx Pharma (PLXP) A Worthy Investment?

Summers Value Partners, an investment management firm, published its “Summers Value Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. The Summers Value Fund LP (“the Fund”) returned 43.4% net for the full year 2021, outpacing the Russell 2000 Index ETF return of 13.7% and the Russell Micro-Cap Index […]

Yahoo | February 21, 2022

PLx Pharma (NASDAQ:PLXP) investors are sitting on a loss of 32% if they invested a year ago

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...

Yahoo | February 16, 2022

PLx Pharma Inc. Proudly Celebrates Go Red for Women Day® 2022 to Support Heart Health Awareness

-- Female-Led Company Strives to Transform Standard of Care in Secondary Prevention of Heart Attack or Clot-Related Stroke with its Innovative New Aspirin Formulation VAZALORE® -- SPARTA, N. J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the mark

Yahoo | February 3, 2022

PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate Communications

SPARTA, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin capsules (

Yahoo | January 19, 2022

Read More 'PLXP' Stories Here

PLXP Price Returns

1-mo N/A
3-mo -49.83%
6-mo -71.98%
1-year -73.86%
3-year -48.95%
5-year -49.22%
YTD -63.55%
2021 45.11%
2020 26.32%
2019 185.62%
2018 -77.83%
2017 -46.09%

Continue Researching PLXP

Want to see what other sources are saying about PLx Pharma Inc's financials and stock price? Try the links below:

PLx Pharma Inc (PLXP) Stock Price | Nasdaq
PLx Pharma Inc (PLXP) Stock Quote, History and News - Yahoo Finance
PLx Pharma Inc (PLXP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5406 seconds.